Milestone Pharmaceuticals is trading 5.34% higher at $0.75; available reports do not identify a specific cause for the move. - Healthcare is up 1.33%, providing supportive sector context. - On October 9, the company reported the first European participant enrolled in its Phase 3 ReVeRA-301 trial; the release did not link the milestone to the share-price increase.